Literature DB >> 12952288

Survivin in brain tumors: an attractive target for immunotherapy.

Masahito Katoh1, Rick Wilmotte, Marie-Claude Belkouch, Nicolas de Tribolet, Gianpaolo Pizzolato, Pierre-Yves Dietrich.   

Abstract

Survivin, a member of the inhibitor of apoptosis proteins gene family, was recently shown to be expressed by tumors originating from different cell lineages. There are also cumulative evidences that spontaneous immune response against survivin derived epitopes may occur. Here, using RT-PCR, Western-blot analysis and immunohistochemistry, we show that survivin is widely expressed by gliomas, meningiomas and schwannomas, both in vitro and in vivo. These data indicate that survivin may serve as an attractive target for immunotherapies designed for brain tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12952288     DOI: 10.1007/BF02700022

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  23 in total

1.  Expression of the tumor-rejection antigen SART1 in brain tumors.

Authors:  T Imaizumi; T Kuramoto; K Matsunaga; S Shichijo; S Yutani; M Shigemori; K Oizumi; K Itoh
Journal:  Int J Cancer       Date:  1999-12-10       Impact factor: 7.396

2.  Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.

Authors:  Amy B Heimberger; Gary E Archer; Laura E Crotty; Roger E McLendon; Allan H Friedman; Henry S Friedman; Darell D Bigner; John H Sampson
Journal:  Neurosurgery       Date:  2002-01       Impact factor: 4.654

3.  Quantitatively determined survivin expression levels are of prognostic value in human gliomas.

Authors:  Arnab Chakravarti; Elizabeth Noll; Peter McL Black; Daniel F Finkelstein; Dianne M Finkelstein; Nicholas J Dyson; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

4.  Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis.

Authors:  S Fukuda; L M Pelus
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

5.  Prognostic significance of survivin expression in diffuse large B-cell lymphomas.

Authors:  C Adida; C Haioun; P Gaulard; E Lepage; P Morel; J Briere; H Dombret; F Reyes; J Diebold; C Gisselbrecht; G Salles; D C Altieri; T J Molina
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

6.  Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation.

Authors:  C Adida; P L Crotty; J McGrath; D Berrebi; J Diebold; D C Altieri
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

7.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

Authors:  P Saas; P R Walker; M Hahne; A L Quiquerez; V Schnuriger; G Perrin; L French; E G Van Meir; N de Tribolet; J Tschopp; P Y Dietrich
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

8.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer.

Authors:  H Kawasaki; D C Altieri; C D Lu; M Toyoda; T Tenjo; N Tanigawa
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

Review 9.  Malignant glioma: should chemotherapy be overthrown by experimental treatments?

Authors:  P Hösli; A P Sappino; N de Tribolet; P Y Dietrich
Journal:  Ann Oncol       Date:  1998-06       Impact factor: 32.976

Review 10.  Survivin apoptosis: an interloper between cell death and cell proliferation in cancer.

Authors:  D C Altieri; P C Marchisio; C Marchisio
Journal:  Lab Invest       Date:  1999-11       Impact factor: 5.662

View more
  14 in total

Review 1.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

2.  Benign tumors from the human nervous system express high levels of survivin and are resistant to spontaneous and radiation-induced apoptosis.

Authors:  Maher Hassounah; Boleslaw Lach; Ayman Allam; Huda Al-Khalaf; Yunus Siddiqui; Nancy Pangue-Cruz; Abeer Al-Omeir; Mohammed N Al-Ahdal; Abdelilah Aboussekhra
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

3.  Lack of prognostic significance of survivin in pediatric medulloblastoma.

Authors:  Roberta Soares Faccion; Regina Moreira Ferreira; Marília Fornaciari Grabois; Theresinha Carvalho Fonseca; Jose Antonio de Oliveira; Raquel Ciuvalschi Maia
Journal:  Pathol Oncol Res       Date:  2011-06-17       Impact factor: 3.201

Review 4.  Chaperone proteins and brain tumors: potential targets and possible therapeutics.

Authors:  Michael W Graner; Darell D Bigner
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

5.  Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays.

Authors:  Jourdan E Stuart; Eriks A Lusis; Adrienne C Scheck; Stephen W Coons; Anita Lal; Arie Perry; David H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2011-01       Impact factor: 3.685

6.  High throughput screening of meningioma biomarkers using a tissue microarray.

Authors:  Eriks A Lusis; Michael R Chicoine; Arie Perry
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

7.  ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

Authors:  Sylwia Ammoun; Clare H Cunliffe; Jeffrey C Allen; Luis Chiriboga; Filippo G Giancotti; David Zagzag; C Oliver Hanemann; Matthias A Karajannis
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

8.  N-(4-Hydroxyphenyl)retinamide induced differentiation with repression of telomerase and cell cycle to increase interferon-gamma sensitivity for apoptosis in human glioblastoma cells.

Authors:  Rajiv Janardhanan; Naren L Banik; Swapan K Ray
Journal:  Cancer Lett       Date:  2008-03-08       Impact factor: 8.679

Review 9.  Brain tumor immunotherapy: an immunologist's perspective.

Authors:  Lois A Lampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

10.  Therapeutic vaccines for malignant brain tumors.

Authors:  Michael P Gustafson; Keith L Knutson; Allan B Dietz
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.